HMNC Brain Health raises $50 million in Series B round and signs Medice deal
German neuroscience company HMNC Brain Health has raised $50 million in the first closing of a Series B financing round and signed a strategic partnership with Medice covering European commercialization of its oral ketamine program.
Medice led the round, with existing investor The Maschmeyer Group also participating. HMNC said the proceeds would support Phase III-readiness activities for two depression programs: Ketabon (ketamine; KET01), an oral prolonged-release ketamine formulation for treatment-resistant depression, and Nelivabon (nelivaptan; BH-200), a biomarker-guided vasopressin V1b receptor antagonist for major depressive disorder.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze